Indirect comparison of the efficacy of cetuximab and cisplatin in squamous cell carcinoma of the head and neck

Current Medical Research and Opinion

Volumn 27, Issue 12, 2011, Pages 2253-2259

  Levy, Adrian R ^a,b   Johnston, Karissa M ^a   Sambrook, Jennifer ^a   Donato, Bonnie ^c   Penrod, John R ^c   Corral, Mitra ^c   Chasen, Martin ^d  

^a ICON PLC   (United Kingdom)

^b DALHOUSIE UNIVERSITY   (Canada)

^c BristolMyers Squibb ^*  (United States)

^d OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

Chemotherapy; Head and neck cancer; Indirect comparisons; Radiation

Indexed keywords

CETUXIMAB; CISPLATIN;

CANCER RADIOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; HAZARD RATIO; HEAD AND NECK CARCINOMA; HUMAN; OVERALL SURVIVAL; QUANTITATIVE ANALYSIS; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MEDLINE;

EID: 81855184870     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.633989     Document Type: Review

References (29)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917
2. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137-50
3. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300
4. Pignon JP, Bourhis J, Designe L, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 2000;355:949-55
5. Pan Q, Gorin MA, Teknos TN. Pharmacotherapy of head and neck squamous cell carcinoma. Expert Opin Pharmacother 2009;10:2291-302
6. Food and Drug Administration. Available at: http://wwwfdagov/NewsEvents/ Newsroom/PressAnnouncements/2006/ucm108609htm 2006 [Last accessed 2 November 2011]
7. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous- cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78
8. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359: 1116-27
9. National Cancer Institute Radiation Therapy Oncology Group. Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer. clinicaltrials.gov NCT00265941 ed
10. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21-8
11. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815-34
12. Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91
13. Song F, Altman DG, Glenny A-M, et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. Br Med J 2003;326:472-5
14. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92-8
15. Forastière AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-8
16. Fountzilas G, Ciuleanu E, Dafni U, et al. Concomitant radiochemotherapy vs radiotherapy alone in patients with head and neck cancer: a hellenic cooperative oncology group phase III study. Med Oncol 2004;21:95-107
17. Huguenin P, Beer KT, Allal A, et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol 2004;22:4665-73
18. Koutcher L, Sherman E, Fury M, et al. Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2011;81:915-22
19. Caudell JJ, Sawrie SM, Spencer SA, et al. Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment. Int J Radiat Oncol Biol Phys 2008;71:676-81
20. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous- cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78
21. Walsh L, Gillham C, Dunne M, et al. Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC). Radiother Oncol 2011;98:38-41
22. Lefebvre J, Pointreau Y, Rolland F, et al. Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): results of the randomized phase II TREMPLIN study. J Clin Oncol 2011;29:abstr 5501
23. Ang KK, Zhang QE, Rosenthal DI, et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). J Clin Oncol 2011;29:abstr 5501
24. Guo JJ, Pandey S, Doyle J, et al. A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy-report of the ISPOR risk-benefit management working group. Value Health 2010; 13:657-66
25. Borenstein M, Hedges L, Higgins J, Rothstein H. Introduction to Meta- Analysis. Sussex: Wiley, 2009
26. Fountzilas G, Ciuleanu E, Dafni U, et al. Concomitant radiochemotherapy vs radiotherapy alone in patients with head and neck cancer: a Hellenic Cooperative Oncology Group Phase III study. Med Oncol 2004;21:95-107
27. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24-35
28. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100:261-9
29. National Comprehensive Cancer Network. Head and Neck Cancers. 2011